Advertisement
 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Oncology

   News

 

 Conferences


   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links
   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

 

 Headlines:

 
 

Back to index

CMF oral regimen

Abstract: Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Prolonged cyclic combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil was evaluated as adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph nodes. After 27 months of study, treatment occurred in 24 per cent of 179 control patients and in 5.3 per cent of 207 women given combination chemotherapy (P less than 10(-6)), the advantage appearing statistically significant in all subgroups of patients. Patients with four or more positive axillary nodes had a higher per cent of relapses than those with fewer nodes. The initial new clinical manifestations occurred in distant sites in 81.5 per cent of relapsed patients. Long-term chemotherapy produced an acceptable toxicity, thus allowing the administration of a high percentage of drug dosage. These results should be considered with caution, since, at present, the effect of this therapy on survival and possible long-term side effects remain unknown.

References
Bonadonna G.  Brusamolino E.  Valagussa P.  Rossi A. Brugnatelli L.  Brambilla C.  De Lena M.  Tancini G.  Bajetta E.  Musumeci R. Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. New England Journal of Medicine.  294(8):405-10, 1976 Feb 19.

Editors Note:
This study was reported in 1976 and is regarded as a landmark study because it was one of the earliest studies to show the efficacy of combination chemotherapy and also because it was one of the earliest justifications for the use of adjuvant chemotherapy.

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


Regimen

Cytoxan......... 100 mg/sqm orally days 1 to 14.
Methotrexate.... 40 mg/sqm IV days 1 and 8.
Fluorouracil.... 600 mg/sqm IV days 1 and 8.
FREQUENCY....... Repeat cycle every 28 days.

     
  Summary Adjuvant CMF vs. control group (no chemotherapy)
  Disease progression 5.3% vs. 24% in the control group
     
   

previous.gif (72x17 -- 0 bytes)

next.gif (72x17 -- 0 bytes)
Article reviewed by:

Dr. Tamer Fouad, M.D.

 

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.